Hard to Treat Diseases Incorporated -HTDS- Cites the Documented Case of Melanoma Cancer Treated with Tubercin Resulting in a Remarkable Recovery.

Business Editors/Health & Medical Writers

DELRAY BEACH, Fla.--(BUSINESS WIRE)--July 21, 2003

Hard to Treat Diseases Incorporated (Pink Sheets:HTDS) Cites documented case of Melanoma Cancer treated with Tubercin(R).

Tubercin(R) is a remarkable immunostimulant that is derived from Mycobacterium Tuberculosis. As an immunostimulant, Tubercin(R) strengthens the human body's own immune system and assists the body in seeking out and combating cancer cells. Tubercin(R) maintains healthy T-cells thus facilitating the killer T-cells to recognize and destroy cancer cells. In effect, as a cancer vaccine Tubercin(R) demonstrates promise of getting the body's immune system to kill tumors the same way it fights off infections. It appears that Tubercin(R) has little or no side effects and is successful in training T-cells to attack and kill the diseased cancer cells. Furthermore, patients have described Tubercin(R) being effective in Pain Management whereby it appears Tubercin(R) as having the high propensity of deadening the nerve endings in specific areas of the body where cancer has caused erosion and consequently much pain. Tubercin(R) is a finished product and ideal for FDA Testing and Approval, as well as arriving at the marketplace as a product for Alternative Medicinal purposes. This is the immediate mission of HTTD.

The Case of the 77-year-old woman diagnosed with terminal Melanoma Cancer. On November 19, 1999, a female in her late 70's was diagnosed with terminal Melanoma Cancer (Acral Lentigious type of Cancer). She was not expected to live but a few months and doctors recommended amputation of the arm at the elbow immediately. This they thought would give her a three month life expectancy. The woman rejected the recommendation and started home from Seoul, Korea to Taegue, Korea in the South where she had originated and was her home town. She heard about the wonders of Tubercin and the works of Dr. Tai Ho Chung at the Kyungpook National University Medical School at Taegue and sought his diagnosis and opinion. After consultation, the Taegue woman agreed to Tubercin(R) injections.

What follow is the results of the woman's Tubercin(R) treatment. First of all, there was no amputation of the arm and after approximately twelve months of receiving an aggressive regimen, including both intralesional and intramuscular injections of Tubercin(R), the 77-year-old Taegue lady's primary tumor became histologically undetectable and she remained free of any known metastases. This meant as of March 16th, 2001 when the official biopsy in effect reported its findings; she was free of any cancer.

This event was published, "Regression of an acral lentigious melanoma with an immunotherapy using a Mycobacterium Tuberculosis-extracted polysaccharide complex (Tubercin(R)) by Tai Ho Chung, Jae Bok Jun, Jae Won Jang and Hai Lee Chung, International Journal of Dermatology, dated January 1st, 2002, Volume 41, London U.K. published by Blackwell Science Ltd. HTTD has confirmed the Taegue lady is alive and well and working in the rice fields of South Korea. She still takes Tubercin(R) shots for good prevention.

Hard to Treat Diseases Incorporated ("HTTD") holds the international marketing rights, except South Korea, to Tubercin, a patented immunostimulant developed for combating Cancer under medical patent (US Patent 6,274,356). The unique properties unlike other cancer products are clearly stated in the abstract of the patent... "Is highly effective in treating various cancer patients without incurring any adverse side effects".

For more information visit the company's website at http://httd.com

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events.